The University of Tokyo and Astellas Pharma Inc. have entered the second phase of their collaboration for co-creating innovative new medicines and medical solutions, called the Astellas Alliance Acceleration Program (AAAP).   In its first phase, from September 2020 to March 2022, AAAP established a base for its collaborative relationship at the university’s Institute for Life Science Research and Education, and the University of Tokyo Center of Innovation. During this period, medical and...